With new Alzheimer's prevention trial, Roche and Genentech may put amyloid hypothesis to ultimate test
If the dozens of trials over the last two decades haven’t yielded a conclusive result, Roche and Genentech may soon finally put the amyloid hypothesis for Alzheimer’s to a final test.
The companies announced on Thursday a new trial to see whether their amyloid-clearing antibody gantenerumab can prevent cognitive decline in patients who already have plaque buildup in their brains but have yet to show memory loss or other cognitive symptoms. The study will enroll 1,200 patients and follow them for four years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.